Our experts, Profs. George Bakris (USA), Peter Rossing (Denmark), and Priya Sumithran (Australia) present 3 cases addressing different aspects of diabetes management in chronic kidney disease.
In this session, the speakers present 3 cases addressing the various stages of CKD in patients with Diabetes from the perspective of an endocrinologist and a nephrologist.
Join endocrinologist Nitin Kapoor (India) and nephrologist Holly Kramer (USA) in an educational session that delves into the epidemiology of obesity in the context of CKD, and the mechanisms leading to new-onset renal disease and the progression of pre-existing CKD. The experts also discuss the current evidence supporting the treatment of obesity in CKD patients. Join them as they explore new pathways and treatment options, emphasizing the importance of a multidisciplinary approach in ...
This case-based session was organized by the International Society of Endocrinology (ISE) and the International Society of Nephrology (ISN) as part of a mutual commitment to advance the management of overlapping endocrinology and kidney diseases worldwide. Join nephrologists Steve Chadban (Australia) and Natasha Rogers (Australia) and endocrinologist Pankaj Shah (USA) in a case-based educational session that discusses endocrine and metabolic complications after a kidney transplant. ...
In this session, our group of international experts; Derek LerRoith (Israel), Kwang-Wei Tham (Singapore), and Wendy Brown (Australia), address obesity complications, lifestyle treatment interventions, pharmacotherapy for obesity, and how to identify the right patient for surgery.
In this session, the speakers give a macro view on obesity by addressing important aspects of the science behind the disease, identifying strategies for the prevention of obesity from a public health perspective, and addressing key aspects of weight reduction, the prevention of weight regain and the prevention of weight gain.
In patients with CKD, the decline in GFR reduces the clearance of insulin and many diabetes medications and raises the risk of hypoglycemia with insulin, sulfonylureas and glinides. GLP1 agonists have cardiovascular benefits, and SGLT2 inhibitors significantly decrease kidney and cardiovascular outcomes making them the class of choice for those with CKD. Targets for glycemic control should be individualized taking CKD into consideration, and glycemic control should be monitored with HbA1c, ...
Metabesity Course. MODULE 2 - Implications of Metabesity: Cardiovascular, renovascular, and glucometabolic dysfunction
This session addresses some of the implications of Metabesity, namely cardiovascular, renovascular, and glucometabolic dysfunction.Developed in collaboration with Dr Mathew John, Dr Perla Carrillo, and Dr Anthonia Ogbera.
Ask the Experts: What is the role of GLP-1 RAs in the current landscape of incretin therapies for T2D?
This course refreshes Primary Care Physicians' knowledge on T2D in recognition of their generalist skills, supporting them to become more comfortable with their critical role in addressing barriers to T2D treatment optimization, focusing on the role of GLP-1RAs as part of the current landscape of incretin therapies for T2D.
The experts discuss efficacy of SGLT2 inhibitors in patients with CKDm, safety of SGLIT2 inhibtiors in patients with CKD, comparative effects of SGLT2i in those with/without type 2 diabetes, efficacy of new agents tested in recent trials for patients with CKD, and safety of new agents tested in recent trials for patients with CKD.
Join Dr Peter Rossing and Dr Mark E Molitch in a conversation about the current management of diabetes in patients with kidney disease.
Increased morbidity and mortality from COVID-19 in patients with Diabetes Mellitus have been noted in those countries hardest hit by the pandemic. This webinar addresses this association and the optimal management of infected patients with Diabetes Mellitus, with an insight into the impact of COVID-19 on the kidney, association of kidney disease with outcomes and management of COVID-19 disease and considerations for the outpatient management of kidney disease patients in the setting of the COVID...
This course explores the definitions of "metabolic syndrome" and "obesity" and will give you the tools to compare and contrast the definition of "obesity" in childhood and adolescence, and recognize the rationale for ethno-specific cutoffs. Developed in collaboration with Dr Hasan Aydın (Turkey).
This course analyses the environmental factors driving obesity, identifies cues during development, plasticity, and determination of the adult phenotype, addresses the role of Endocrine Disruptive Chemicals and the central nervous system in obesity, and gives an insight into the different genetic causes of obesity.Developed in collaboration with Dr Ankia Coetzee (South Africa).
This course explores the advantages and limitations of different anthropometric indicators, analyses the importance of assessing body composition in clinical practice and the concept of Normal Weight Obesity, and gives an insight into emerging concepts in obesity assessment.Developed in collaboration with Dr Nitin Kapoor (India).
This interactive webinar series organized by the mdBriefCase Group has assembled a panel of diabetes experts to discuss new and emerging treatment options and their impact on individualized care.
This course will give you an insight into a profound and worldwide paradigm change in the treatment of Type 2 Diabetes and the latest cardiovascular and renal protective effects with Type 2 Diabetes medications.